检验医学与临床
檢驗醫學與臨床
검험의학여림상
JOURNAL OF LABORATORY MEDICINE AND CLINICAL SCIENCES
2015年
15期
2185-2187
,共3页
呼吸机相关性肺炎%氨溴索%感染%病情预后
呼吸機相關性肺炎%氨溴索%感染%病情預後
호흡궤상관성폐염%안추색%감염%병정예후
ventilator associated pneumonia%ambroxol%infection%disease prognosis
目的:探讨大剂量盐酸氨溴索治疗呼吸机相关性肺炎(VAP)对其感染控制情况及病情预后的影响,为临床用药方案的制定提供数据支撑。方法选取延安大学附属医院急危重症科2009年2月至2014年6月收治的 VAP 患者78例,采用随机数字表法进行分组,分别设为研究组和对照组,每组各39例。2组患者均开展常规对症支持治疗,即根据药敏试验结果给予相应抗生素、营养支持、氧疗等措施,研究组在此基础上采取大剂量盐酸氨溴索方案治疗,对照组则采取小剂量盐酸氨溴索方案治疗。比较2组患者在治疗前及治疗后第1、2周后炎性控制、病情预后及用药安全性情况。结果2组治疗前白细胞计数、中性粒细胞分类、临床肺部感染(CPIS)评分及氧合指数差异无统计学意义(P>0.05);治疗后第1、2周后,研究组白细胞计数、中性粒细胞分类、CPIS 评分均低于对照组,差异有统计学意义(P<0.05);氧合指数高于对照组,差异有统计学意义(P<0.05)。研究组住院时间及机械通气时间均短于对照组,差异有统计学意义(P<0.05),再次插管发生率及病死率均低于对照组,差异有统计学意义(P<0.05)。2组给药期间不良反应发生率差异无统计学意义(P >0.05)。结论大剂量盐酸氨溴索方案治疗VAP 能有效改善其临床症状,利于炎性控制,且能降低病死率,值得在临床上进一步推广。
目的:探討大劑量鹽痠氨溴索治療呼吸機相關性肺炎(VAP)對其感染控製情況及病情預後的影響,為臨床用藥方案的製定提供數據支撐。方法選取延安大學附屬醫院急危重癥科2009年2月至2014年6月收治的 VAP 患者78例,採用隨機數字錶法進行分組,分彆設為研究組和對照組,每組各39例。2組患者均開展常規對癥支持治療,即根據藥敏試驗結果給予相應抗生素、營養支持、氧療等措施,研究組在此基礎上採取大劑量鹽痠氨溴索方案治療,對照組則採取小劑量鹽痠氨溴索方案治療。比較2組患者在治療前及治療後第1、2週後炎性控製、病情預後及用藥安全性情況。結果2組治療前白細胞計數、中性粒細胞分類、臨床肺部感染(CPIS)評分及氧閤指數差異無統計學意義(P>0.05);治療後第1、2週後,研究組白細胞計數、中性粒細胞分類、CPIS 評分均低于對照組,差異有統計學意義(P<0.05);氧閤指數高于對照組,差異有統計學意義(P<0.05)。研究組住院時間及機械通氣時間均短于對照組,差異有統計學意義(P<0.05),再次插管髮生率及病死率均低于對照組,差異有統計學意義(P<0.05)。2組給藥期間不良反應髮生率差異無統計學意義(P >0.05)。結論大劑量鹽痠氨溴索方案治療VAP 能有效改善其臨床癥狀,利于炎性控製,且能降低病死率,值得在臨床上進一步推廣。
목적:탐토대제량염산안추색치료호흡궤상관성폐염(VAP)대기감염공제정황급병정예후적영향,위림상용약방안적제정제공수거지탱。방법선취연안대학부속의원급위중증과2009년2월지2014년6월수치적 VAP 환자78례,채용수궤수자표법진행분조,분별설위연구조화대조조,매조각39례。2조환자균개전상규대증지지치료,즉근거약민시험결과급여상응항생소、영양지지、양료등조시,연구조재차기출상채취대제량염산안추색방안치료,대조조칙채취소제량염산안추색방안치료。비교2조환자재치료전급치료후제1、2주후염성공제、병정예후급용약안전성정황。결과2조치료전백세포계수、중성립세포분류、림상폐부감염(CPIS)평분급양합지수차이무통계학의의(P>0.05);치료후제1、2주후,연구조백세포계수、중성립세포분류、CPIS 평분균저우대조조,차이유통계학의의(P<0.05);양합지수고우대조조,차이유통계학의의(P<0.05)。연구조주원시간급궤계통기시간균단우대조조,차이유통계학의의(P<0.05),재차삽관발생솔급병사솔균저우대조조,차이유통계학의의(P<0.05)。2조급약기간불량반응발생솔차이무통계학의의(P >0.05)。결론대제량염산안추색방안치료VAP 능유효개선기림상증상,리우염성공제,차능강저병사솔,치득재림상상진일보추엄。
Objective To explore the influence of large dose of ambroxol hydrochloride in treating ventilator‐associated pneumonia(VAP) on the infection control and prognosis to provide the data support for formulating the clinical medication scheme .Methods 78 with VAP in the emergency department of our hospital from February 2009 to June 2014 were selected and divided into the study group and the control group by adopting the random number ta‐ble method ,39 cases in each group .Two groups were carried out the conventional symptomatic and supportive treat‐ment ,i .e .giving the corresponding measures of antibiotics ,oxygen therapy and nutrition support according to the re‐sults of drug susceptibility test .On this basis the study group took the large dose of ambroxol hydrochloride therapy , while the control group adopted the small dose of ambroxol hydrochloride therapy .Records of patients the inflamma‐tion control ,disease prognosis and medication safety situation before treatment and at the end of 1 ,2 weeks after treatment in the two groups were recorded for making a comparison .Results The white blodd cell count ,neutrophil classification ,clinic pulmonary infection score(CPIS) score and oxygenation index before treatment had no statistical difference between the two groups(P> 0 .05) ;which at the end of 1 ,2 weeks after treatment in the study group were lower than the those in the control group( P < 0 .05) ,while the oxygen index was higher than that of the control group(P< 0 .05) .The hospital stay and duration of mechanical ventilation in the study group were shorter than those in the control group(P< 0 .05) ,moreover the reintubation incidence rate and mortality rate were lower than those in the control group(P < 0 .05) .The incidence rates of adverse reactions during medication period had no statistically significant difference between the two groups(P> 0 .05) .Conclusion The large dose of ambroxol hydrochloride regi‐men for treating VAP can effectively improve the clinical symptoms ,conduces to the control of inflammation ,and can reduce the mortality rate and deserves to be popularized in clinic .